Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $455.45, denoting a -1% move from the preceding trading day.

Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant ...

According to a Worker Adjustment Retraining Notification written by Vertex to the R.I. Department of Labor and Training, ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Aries Wealth Management has tiptoed into biotech by acquiring 605 shares of Vertex Pharmaceuticals, valued around $293,000. Other hedge funds also took notice, adjusting their positions during the ...

CCM Investment Advisers gave Vertex Pharmaceuticals a vitamin shot by upping its stake 24.1% in Q1. They purchased an ...